New oral drug trial targets Tough-to-Treat lung cancer mutation
Disease control
Recruiting now
This study is testing a new oral medication called JBI-802, given alone or with an existing immunotherapy drug (pembrolizumab), for people with advanced non-small cell lung cancer that has a specific genetic change called an STK11 mutation. The main goals are to see if the treatm…
Phase: PHASE2 • Sponsor: The Christ Hospital • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC